Physician profile
Sandra A Ho
NPI 1659680411
$5,591.42
in general payments reported to CMS, 2019-2025
31 companies · $884 in 2025
The $884 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $645 · 2021: $842 · 2022: $881 · 2023: $921 · 2024: $548 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,352.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $949.10 | 2019-2025 | Fasenra, Tezspire, Symbicort |
| Glaxosmithkline, LLC. | $681.35 | 2019-2025 | Nucala, Trelegy Ellipta |
| Optinose US, INC. | $632.18 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $562.23 | 2019-2023 | Dupixent |
| Genzyme Corporation | $485.49 | 2019-2025 | |
| Amgen INC. | $332.72 | 2022-2025 | Tezspire, Actimmune |
| Takeda Pharmaceuticals U.S.A., INC. | $213.53 | 2020-2025 | Takhzyro, Eohilia |
| Novartis Pharmaceuticals Corporation | $183.13 | 2019-2025 | |
| Kaleo, INC. | $178.43 | 2019-2022 | |
| Csl Behring | $143.06 | 2019 | |
| Pfizer INC. | $137.17 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $124.03 | 2025 | Neffy |
| Octapharma USA, INC. | $108.65 | 2020-2023 | Octagam Immune Globulin (Human) |
| Genentech USA, INC. | $104.40 | 2019-2025 | Xolair |
| Shire North American Group INC | $84.65 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bio Products Laboratory USA, INC. | $77.93 | 2020-2023 | Coagadex, Gammaplex |
| Blueprint Medicines Corporation | $72.36 | 2024-2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $69.83 | 2024-2025 | Orladeyo |
| Phadia US INC. | $56.52 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.48 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $52.65 | 2020-2021 | |
| Grifols USA, LLC | $45.29 | 2024-2025 | Xembify |
| Horizon Therapeutics Plc | $39.79 | 2020 | |
| Alk-Abello, INC | $38.24 | 2019 | |
| Pharming Healthcare, INC. | $36.06 | 2021-2022 | |
| Leo Pharma INC. | $29.91 | 2024 | Adbry |
| Ionis Pharmaceuticals, INC. | $25.42 | 2025 | Dawnzera |
| Lilly USA, LLC | $23.99 | 2025 | Ebglyss |
| Gc Biopharma USA, INC. | $21.00 | 2025 | Alyglo |
| Sunovion Pharmaceuticals INC. | $16.81 | 2019 | |
| Merck Sharp & Dohme LLC | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.